Anti-Human Siglec-3/CD33 Reference Antibody (Lintuzumab, RUO) (HB185026)

Name: Anti-Human Siglec-3/CD33 Reference Antibody (Lintuzumab, RUO)
Brand: abinScience
SKU: HB185026
Price: 176 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HB185026
説明	Lintuzumab (HB185026) is a research-grade recombinant antibody targeting CD33. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性	Human
アプリケーション	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	IgG1-kappa
発現システム	Mammalian cells
ターゲット	Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
エンドトキシンレベル	< 10 EU/mg
純度	>95% purity as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	P20138
形態	Liquid
保存バッファー	0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	225Ac-lintuzumab, HuM195, SGN-33, SMARTM195, HuM195, 166089-32-3
背景	Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg). 1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343 2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212 3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323 4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872 5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109 6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905 7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955 8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798
注意事項	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Anti-LASV GPC Recombinant Antibody (Fab 37.7) (VK453013) Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)